Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 16, 2021Cancer ResearchOpen Access

Epigenetic Alterations and Mechanisms That Drive Resistance to Targeted Cancer Therapies

View Full Paper
Ask AI
Bookmark
Share

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

A 2021 study studied this question.

synapsesocial.com/papers/6a840348a47fb2e1cdb28fbahttps://doi.org/10.1158/0008-5472.can-21-1606
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Targeted therapies in breast cancer: New challenges to fight against resistance2017 · 359 citations
  2. 2Embryonic transcription factor SOX9 drives breast cancer endocrine resistance2017 · 114 citations
  3. 3Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer2016 · 3,400 citations
  4. 4MEK inhibitor resistance mechanisms and recent developments in combination trials2020 · 197 citations
  5. 5Registered report: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion2014 · 17 citations